An observational study in GastroIntestinal Bleeding, sponsored by Xingshun Qi. Recruiting at 23 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-07.
Sponsored by Xingshun Qi · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Gastrointestinal Hemorrhage with a site in China — 8 open to participants now, 9 under way, 1 of them phase 3. Gastrointestinal Hemorrhage · China.
Among the 40 studies in Gastrointestinal Hemorrhage with a site in China, this one is one of 2 that started in 2022, is one of 7 observational ones, and was the 22nd registered.
338 studies on the registry are indexed under Gastrointestinal Hemorrhage; 77 are open to participants now.
Browse Gastrointestinal Hemorrhage studies →8 of the 40 studies in Gastrointestinal Hemorrhage with a site in China are open now. Recruiting first, the newest first:
Sixth Affiliated Hospital, Sun Yat-sen University · Sites in China
Ages 18–75
Sixth Affiliated Hospital, Sun Yat-sen University · Sites in China
Ages 18–75
Chinese University of Hong Kong · Sites in China
Ages 18+
Chinese University of Hong Kong · Sites in China, Hong Kong, Thailand
Ages 18+
China-Japan Friendship Hospital · Sites in China
Ages 18–90
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 49 Gastrointestinal Hemorrhage studies recruiting now, 39 (80%) set no upper age limit and 4 (8%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 5 · Phase 4 5
First in 2004; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 3,000 is above the median of 176 across 117 observational studies indexed under Gastrointestinal Hemorrhage.
Median enrollment 101 across the 33 interventional studies, 476 across the 7 observational. Of the 21 that completed or were terminated, 1 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 40 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Xingshun Qi as lead sponsor.
Xingshun Qi has 1 study filed under Gastrointestinal Hemorrhage — fewer than ten, so there is no comparison to draw.
2 of the studies in Gastrointestinal Hemorrhage with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07129031Phase 3Xijing HospitalOptimization Strategies for Blood Transfusion Protocols in the Emergency Treatment of Hemorrhagic Shock | 2027-06-30 |
| NCT06776029Sixth Affiliated Hospital, Sun Yat-sen UniversityFecal Microbiota Transplantation for Radiation-Induced Proctopathy | 2027-03-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 40 studies in Gastrointestinal Hemorrhage with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Acute gastrointestinal bleeding is potentially lethal in liver cirrhosis. Accurate assessment of prognosis is critical in a timely fashion. A novel model, CAGIB score, has been developed based on our Chinese multicenter retrospective study. Now, a prospective, international multicenter, observational study will be performed to further compare the performance of CAGIB versus Child-Pugh and MELD scores for evaluating the in-hospital mortality of patients with liver cirrhosis and acute gastrointestinal bleeding.
Patients with liver cirrhosis and acute gastrointestinal bleeding
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Mortality
Death caused by any events during hospitalizations.
Time frame: An average of 1-6 weeks, from admission to discharge
Failure to control bleeding within 5 days
Failure is defined as death or need to change therapy defined by one of the following criteria within 5 days: 1) Fresh hematemesis or nasogastric aspiration of ≥100 ml of fresh blood ≥2 h after the start of a specific drug treatment or therapeutic endoscopy; 2) Development of hypovolaemic shock; 3) 3g drop in hemoglobin (9% drop of hematocrit) within any 24 hours period if no transfusion is administered.
Time frame: 5 days
Plan to share: No
Started Jan 2022 (actual). Primary completion is estimated for Dec 2025, 47 months after the start.
Of 42 non-industry observational studies under Gastrointestinal Hemorrhage, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 63. This study's planned 47 months is above that.
Counting every sponsor, half of 47 studies reached it within 36 months; a quarter within 24 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.